Price
No data yet.
Social Signal Score
Analyst Ratings
52 analystsRevenue
$1.29B+9356.80%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Yvonne L. Greenstreet
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 2,500
- Beta
- 0.30
- Country
- US
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 4.79
Financials
Revenue
$1.29B+9356.8%Net Income
$164.49MEBITDA
$244.72MFree Cash Flow
$40.64MEPS (diluted)
$1.20Shares Outstanding (diluted)
138.25M+61.3%Operating Expenses
$761.06MCash & Debt
$3.31BReturn of Capital
$0.00Revenue by Segment (annual)
$3.71BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $3.71B | $313.75M | $2.39 |
| 2024 | $2.25B | $-278.16M | $-2.18 |
| 2023 | $1.83B | $-440.24M | $-3.52 |
| 2022 | $1.04B | $-1.13B | $-9.30 |
| 2021 | $844.29M | $-852.82M | $-7.20 |
| 2020 | $492.85M | $-858.28M | $-7.46 |
| 2019 | $219.75M | $-886.12M | $-8.11 |
| 2018 | $74.91M | $-761.50M | $-7.57 |
| 2017 | $89.91M | $-490.87M | $-5.42 |
| 2016 | $47.16M | $-410.11M | $-4.79 |
| 2015 | $41.10M | $-290.07M | $-3.45 |
| 2014 | $50.56M | $-360.39M | $-4.85 |
| 2013 | $47.17M | $-89.22M | $-1.45 |
| 2012 | $66.72M | $-106.01M | $-2.11 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $3.52
- Implied price
- $63.34
- Return from $219.72
- -22.0% a year
To earn 15.0% a year on these assumptions you'd need to buy at $31.49 — -85.7% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 12 | 15 | 18 | 21 | 24 |
|---|---|---|---|---|---|
| -2.0% | -34.8% | -31.8% | -29.2% | -27.0% | -25.1% |
| 3.0% | -31.4% | -28.3% | -25.6% | -23.3% | -21.2% |
| 8.0% | -28.1% | -24.8% | -22.0% | -19.6% | -17.4% |
| 13.0% | -24.8% | -21.3% | -18.4% | -15.9% | -13.6% |
| 18.0% | -21.4% | -17.9% | -14.8% | -12.1% | -9.8% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
0Social Signal Score
Mentions (24)
- Newsglobenewswire.com·1d ago·Negative
Alnylam Pharmaceuticals, Inc. (ALNY) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation BENSALEM, Pa., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith continues its investigation on behalf of Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (NASDAQ: ALNY) investors concerning the Company's possible violations of federal securities laws.
View source ↗ - Newsglobenewswire.com·3d ago·Negative
Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz LOS ANGELES, Oct. 02, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz continues its investigation of Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (NASDAQ: ALNY) on behalf of investors concerning the Company's possible violations of federal securities laws.
View source ↗ - Newsseekingalpha.com·7d ago·Neutral
Alnylam Pharmaceuticals: More Than Meets The Eye After CARDIO-TTRansform Alnylam Pharmaceuticals, Inc. shares have fallen 18% amid concerns over its ATTR-CM franchise following AstraZeneca/Ionis trial failure. I see pessimism as understandable but overdone; nucresiran's superior TTR knockdown and trial design differences support a credible case for TRITON-CM success. Even if TRITON-CM fails, Amvuttra's first-line share gains and Alnylam's diverse pipeline mitigate downside risk.
View source ↗ - Newszacks.com·7d ago·Neutral
4 RNA Therapeutics Stocks Leading the Next Wave of Innovation RNA therapeutics are gaining momentum as Alnylam, Ionis, Wave Life Sciences and Arcturus advance innovative treatments targeting a range of diseases.
View source ↗ - Newsfool.com·8d ago·Positive
18 of 21 Analysts Still Think Alnylam Stock Is a Buy. Here's Why They're Right. Wall Street analysts are overwhelmingly bullish about Alnylam. The stock's attractive valuation and the company's growth prospects appear to support their enthusiasm.
View source ↗ - News (RSS)seekingalpha·10d ago·Positive
Alnylam Needs Stronger Amvuttra Execution To Justify More Upside
View source ↗ - News (Marketaux)seekingalpha.com·10d ago·Positive
Alnylam Needs Stronger AMVUTTRA Execution To Justify More Upside (NASDAQ:ALNY) Although Alnylam Pharmaceut[+312 characters]
View source ↗ - Newsmarketbeat.com·15d ago·Positive
Alnylam Highlights AMVUTTRA Momentum, Resets 2026 TTR Revenue Outlook Alnylam Pharmaceuticals NASDAQ: ALNY highlighted continued momentum for its AMVUTTRA treatment in transthyretin-mediated cardiomyopathy, while outlining a pipeline of upcoming clinical catalysts and discussing changes in the market that prompted a revision to its 2026 TTR franchise revenue outlook.
View source ↗ - Newsmarketbeat.com·16d ago·Neutral
Alnylam's Zilebesiran Targets Twice-Yearly Blood Pressure Control in ZENITH Trial Alnylam Pharmaceuticals NASDAQ: ALNY outlined its strategy for advancing zilebesiran, an investigational RNA interference, or RNAi, therapy designed to provide sustained blood-pressure control with twice-yearly dosing for people with uncontrolled hypertension and elevated cardiovascular risk.
View source ↗ - News (RSS)seekingalpha·18d ago·Positive
Alnylam Pharmaceuticals, Inc. (ALNY) Discusses Zilebesiran and the Potential of RNAi Therapeutics for Continuous Blood Pressure Control Transcript
View source ↗ - News (RSS)seekingalpha·18d ago·Neutral
Alnylam Pharmaceuticals, Inc. (ALNY) Discusses Zilebesiran and the Potential of RNAi Therapeutics for Continuous Blood Pressure Control - Slideshow
View source ↗ - Newsseekingalpha.com·18d ago·Positive
Alnylam Pharmaceuticals, Inc. (ALNY) Discusses Zilebesiran and the Potential of RNAi Therapeutics for Continuous Blood Pressure Control Transcript Alnylam Pharmaceuticals, Inc. (ALNY) Discusses Zilebesiran and the Potential of RNAi Therapeutics for Continuous Blood Pressure Control Transcript
View source ↗ - Newsseekingalpha.com·27d ago·Positive
Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
View source ↗ - Newszacks.com·34d ago·Neutral
4 Rare Disease Drugmakers With Strong Long-Term Growth Prospects ALNY, BMRN, RARE and BBIO offer rare-disease growth potential through strong products, pipeline catalysts and high unmet medical needs.
View source ↗ - News (Marketaux)gurufocus.com·36d ago·Neutral
ALNY Looks 55.6% Undervalued on GF Value™ Amid New Cardiovascular RNAi Data On August 30, 2026, Alnylam <em[+259 characters]
View source ↗ - News (RSS)seekingalpha·36d ago·Negative
Alnylam data support Amvuttra across ATTR patient groups, advance hypertension drug case
View source ↗ - Newsbusinesswire.com·37d ago·Negative
…gth in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR) patien…
View source ↗ - Newsbusinesswire.com·43d ago·Negative
…h in RNAi-Powered TTR Silencing and Continued Progress in Hypertension at ESC Congress 2026 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that it will present new clinical and real-world data across its transthyretin-mediated amyloidosis (ATTR) and hypertension programs at the European Society of Cardiology (ESC) Congress 2026, taking place August 28-31, 2026, in Munich, Germany. These presentations add to …
View source ↗ - Newsglobenewswire.com·47d ago·Negative
Alnylam Pharmaceuticals, Inc. (ALNY) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation BENSALEM, Pa., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Law Offices of Howard G.
View source ↗ - Newsglobenewswire.com·47d ago·Negative
Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz LOS ANGELES, Aug. 19, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz continues its investigation of Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (NASDAQ: ALNY) on behalf of investors concerning the Company's possible violations of federal securities laws.
View source ↗ - News (RSS)fool·51d ago·Negative
Why the Alnylam Sell-Off Looks Overdone -- and What Investors Are Missing Yes, Alnylam has had some bad news. But the bad news isn't as horrible as many think.
View source ↗ - Newsfool.com·51d ago·Negative
Why the Alnylam Sell-Off Looks Overdone -- and What Investors Are Missing Alnylam's stock has plunged due to a revenue guidance cut and other concerns. However, the full story for this biotech innovator is more positive than meets the eye.
View source ↗ - Newsglobenewswire.com·54d ago·Negative
Alnylam Pharmaceuticals, Inc. (ALNY) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Continuing Securities Fraud Investigation BENSALEM, Pa., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith continues its investigation on behalf of Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (NASDAQ: ALNY) investors concerning the Company's possible violations of federal securities laws.
View source ↗ - Newsglobenewswire.com·54d ago·Negative
Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz LOS ANGELES, Aug. 12, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz continues its investigation of Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (NASDAQ: ALNY) on behalf of investors concerning the Company's possible violations of federal securities laws.
View source ↗
Earnings
Thu, Oct 29(in 3 weeks)
Consensus estimate $1.77 per share
Typical surprise +6.2% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Jul 30$1.21 vs $1.63miss
- Thu, Apr 30$1.51 vs $0.87beat
- Thu, Feb 12$0.82 vs $1.16miss
- Thu, Oct 30$1.84 vs $0.56beat
- Thu, Jul 31$-0.51 vs $-0.54beat
- Thu, May 1$-0.44 vs $-0.89beat
Estimates and results for ALNY via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ALNY officers and directors.
- Bought
- —
- Sold
- $7.4m
0 trades
72 trades
- Pyott David E Isold
- Pyott David E Isold
- Pyott David E Isold
- Pyott David E Isold
- Pyott David E Isold
- Mclaughlin Melissasold
- Mclaughlin Melissasold
- Mclaughlin Melissasold
28 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Cory Bookersenate · NJ · disclosed Sep 9, 2026 (29d later)Sell$1,001 - $15,000
- Jefferson Shrevehouse · IN06 · disclosed Jun 23, 2025 (42d later)Sell$15,001 - $50,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Feb 15, 2024 (35d later)Buy$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Feb 15, 2024 (17d later)Sell$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Jan 7, 2024 (27d later)Sell$1,001 - $15,000
- Daniel Goldmanhouse · NY10 · disclosed Apr 17, 2023 (42d later)Buy$15,001 - $50,000
- Ro Khannahouse · CA17 · disclosed Mar 8, 2023 (26d later)Sell$1,001 - $15,000
- Daniel Goldmanhouse · NY10 · disclosed Feb 24, 2023 (24d later)Sell$15,001 - $50,000
- Ro Khannahouse · CA17 · disclosed Jan 3, 2023 (28d later)Buy$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Oct 16, 2022 (18d later)Buy$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Dec 9, 2020 (26d later)Sell$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed May 13, 2020 (37d later)Buy$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Nov 16, 2018 (29d later)Sell$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Oct 2, 2018 (123d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.